Electrical Brain Stimulation for College Students With Short-Form Video Addiction: Effects and Mechanisms

November 6, 2026 updated by: Beijing Normal University

Effects and Mechanisms of High-Definition Transcranial Direct Current Stimulation (HD-tDCS) Intervention on Short-Form Video Addiction

The researchers will test whether high-definition transcranial direct current stimulation (HD-tDCS) combined with real-time short-form video cue exposure can reduce addiction severity and daily usage time in college students with problematic short-form video use. By modulating the dorsolateral prefrontal cortex, this study aims to explore whether the treatment improves executive function (such as self-control and risk decision-making) and emotional-cognitive processes (such as craving and attentional bias). Assessments will be conducted before, immediately after the 2-week intervention, and at a 4-week follow-up, using both subjective surveys and objective computer cognitive tasks. Results could pave the way for a low-cost, non-invasive, and scalable intervention strategy to address the growing public health concern of short-form video addiction among young adults.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Over the past few years, problematic short-form video use has emerged as a significant public health concern among college students, associated with impaired executive function, academic decline, and emotional distress. Neuroimaging studies suggest that excessive short-form video consumption is linked to hypoactivity in the dorsolateral prefrontal cortex (dlPFC), which disrupts the balance between cognitive control and reward-driven habits. However, evidence-based non-pharmacological interventions for short-form video addiction remain scarce.

This study builds upon the dual-pathway model of internet addiction and utilizes a high-definition tDCS (HD-tDCS) protocol with a 4x1 ring configuration targeting the right dlPFC (center anode with 4 surrounding return electrodes) to restore prefrontal control. Participants will receive 10 daily HD-tDCS sessions over 2 consecutive weeks. Crucially, to enhance the targeted therapeutic effect, participants will undergo concurrent cue exposure-watching short-form videos on their personal mobile phones for 12 minutes during each 15-minute active or sham HD-tDCS session.

This randomized, double-blind, sham-controlled trial (N=82) employs a longitudinal design with three assessment time points (baseline, post-intervention at week 2, and a 4-week follow-up). We hypothesize that active HD-tDCS will significantly reduce addiction symptoms and usage duration compared to sham. Furthermore, we propose a parallel mediation model to explore the underlying mechanisms: specifically, whether the intervention effect is mediated by improvements in executive function (response inhibition and risk decision-making) and emotional-cognitive pathways (reductions in craving and attentional bias). Results may inform the development of scalable, neuroplasticity-based interventions to mitigate digital addiction and promote mental well-being in young adults.

The sample size was determined a priori using G*Power software (version 3.1.9.7). Based on the effect size (Cohen's f = 0.35) derived from previous meta-analytic findings regarding multiple-session tDCS interventions, assuming an alpha error probability of 0.05, a statistical power of 0.80, 2 groups, and 3 repeated measurements (i.e., pre-test, post-test, and 4-week follow-up), a minimum total sample size of 82 participants is required.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
82

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • China
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100088
        • Department of Psychology, Beijing Normal University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 30 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age between 18 and 30 years.
  • Currently enrolled as a university student.
  • Right-handed.
  • Meets the threshold for problematic short-form video use, as assessed by the Short-form Video Addiction Scale.
  • Primary use: The participant's primary problematic internet use is short-form videos, rather than other behaviors such as online gaming.

Exclusion Criteria:

  • Diagnosed psychiatric disorders.
  • History of neurological disease or traumatic brain injury.
  • History of epilepsy or a family history of epilepsy.
  • Presence of medical implants (e.g., cardiac pacemakers, cochlear implants).
  • Currently receiving pharmacological or psychological treatment.
  • History of receiving any non-invasive brain stimulation (e.g., tDCS, TMS, or tACS) within the past year.
  • Any other contraindications to HD-tDCS (e.g., history of skin lesions/scalp conditions at the electrode sites) or severe physical diseases identified during safety screening.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Active HD-tDCS Group

Participants receive active high-definition transcranial direct current stimulation (HD-tDCS) using a NeuroConn stimulator. A 4x1 ring electrode configuration is applied: the center anodal (positive) electrode is placed over the right dorsolateral prefrontal cortex (F4), surrounded by four cathodal (negative) return electrodes. The stimulation is delivered at 1.5 mA for 15 minutes. Participants receive one session per day, 5 days per week, for 2 consecutive weeks.
Device: Active High-Definition Transcranial Direct Current Stimulation (Active HD-tDCS)

Description: Active HD-tDCS is delivered using a NeuroConn device with a 4x1 ring configuration (center anodal electrode over the right dlPFC, surrounded by 4 cathodal returns). The stimulation is delivered at 1.5 mA for 15 minutes. Participants receive 10 sessions over 2 consecutive weeks (5 days/week). Concurrently during the stimulation, participants watch short-form videos on their mobile phones for approximately 14-15 minutes (using the same platform identified at baseline). A pre-programmed active code ensures strict double-blinding.
Sham Comparator: Sham HD-tDCS Group

Participants receive sham HD-tDCS using the identical NeuroConn device, 4x1 ring electrode configuration, and procedure as the active group. The device delivers a brief current (ramped up and down over 30 seconds) at the beginning of the 15-minute session to mimic the initial skin sensation, but the current is turned off for the remainder of the session. Participants receive one session per day, 5 days per week, for 2 consecutive weeks.
Device: Sham High-Definition Transcranial Direct Current Stimulation (Sham HD-tDCS)

Description: Sham HD-tDCS uses the identical NeuroConn device and 4x1 ring configuration as the active group. The current is ramped up for 30 seconds and then turned off for the remainder of the 15-minute session to mimic the initial skin sensation. Participants receive 10 sessions over 2 consecutive weeks (5 days/week). Concurrently during the sham stimulation, participants watch short-form videos on their mobile phones for approximately 14-15 minutes (using the same platform identified at baseline). A pre-programmed sham code ensures strict double-blinding.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in Short-form Video Addiction Scale Score
Time Frame: Baseline (Pre-test), Week 2 (Post-test), and Follow-up at 4 weeks after the intervention

Assessed using the 25-item Short-form Video Addiction Scale, which includes two dimensions: Addictive Dependence and Negative Consequence. Each item is scored on a 7-point Likert scale (1 = strongly disagree, 7 = strongly agree). The total score ranges from 25 to 175. A higher score indicates a more severe level of short-form video addiction.
Baseline (Pre-test), Week 2 (Post-test), and Follow-up at 4 weeks after the intervention
Change in Average Daily Short-form Video Use Duration
Time Frame: Baseline (Pre-test), Week 2 (Post-test), and Follow-up at 4 weeks after the intervention

Self-reported average time (in minutes) spent watching short-form videos per day over the past week. A higher duration indicates more excessive use.
Baseline (Pre-test), Week 2 (Post-test), and Follow-up at 4 weeks after the intervention

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change in Executive Function Composite Score (SSRT & BART)
Time Frame: Baseline (Pre-test), Week 2 (Post-test), and Follow-up at 4 weeks after the intervention

A composite executive function score will be derived using Exploratory Factor Analysis (EFA) from two tasks: (1) Stop-Signal Reaction Time (SSRT) from the Stop-Signal Task, and (2) Adjusted Average Pumps (AAP) from the Balloon Analogue Risk Task (BART). The factor score extracted from the EFA will serve as the composite indicator, accounting for the relative weighting of each measure. Factor scores will be oriented such that higher values indicate better overall executive function.
Baseline (Pre-test), Week 2 (Post-test), and Follow-up at 4 weeks after the intervention
Change in Emotion-Cognition Composite Score (Craving, ABS, ER)
Time Frame: Baseline (Pre-test), Week 2 (Post-test), and Follow-up at 4 weeks after the intervention

A composite emotion-cognition score will be derived using Exploratory Factor Analysis (EFA) from three measures: (1) Craving Score, (2) Attentional Bias Score (ABS) from the dot-probe task, and (3) Emotion Regulation Score. The factor score extracted from the EFA will serve as the composite indicator to capture the shared variance among these measures. Factor scores will be oriented such that higher values indicate more favorable emotional-cognitive outcomes.
Baseline (Pre-test), Week 2 (Post-test), and Follow-up at 4 weeks after the intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Beijing Normal University

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
National Natural Science Foundation of China

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 15, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 31, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 30, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 6, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 6, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 12, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 12, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 6, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
October 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • BNU202610120439

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings